GlassScriptPhysician profile
Pareed Aliyar
NPI 1780686832
$2,780.61
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $669 · 2021: $553 · 2022: $268 · 2023: $521 · 2024: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.56 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $439.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $328.70 | 2019-2024 | Verquvo |
| Amgen INC. | $275.61 | 2019-2024 | Prolia, Evenity, Otezla |
| E.R. Squibb & Sons, L.L.C. | $221.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $201.59 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.51 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $158.54 | 2019-2022 | |
| Lilly USA, LLC | $119.33 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $112.47 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $94.98 | 2019-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $80.51 | 2021-2022 | |
| Amarin Pharma, INC. | $59.28 | 2020-2021 | |
| Glaxosmithkline, LLC. | $55.21 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $53.29 | 2023-2024 | |
| Lundbeck LLC | $51.20 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.23 | 2020-2022 | |
| Abbott Laboratories | $42.78 | 2021 | |
| Sanofi Pasteur INC. | $42.59 | 2023 | |
| Lucid Diagnostics INC. | $31.65 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.52 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $22.61 | 2023 | |
| Medicure Pharma INC. | $21.55 | 2021 | |
| Philips North America LLC | $21.43 | 2019 | |
| Recordati_rare_diseases_inc. | $20.44 | 2024 | Signifor Lar, Isturisa |
| Boston Scientific Corporation | $15.51 | 2020 | |
| Itamar Medical INC | $15.34 | 2023 | Watchpatone |
| Radius Health, INC. | $14.96 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.76 | 2021 | |
| Gilead Sciences, INC. | $14.06 | 2019 | |
| Medtronic Vascular, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pareed Aliyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.